Prelim report points to anti-competitive practices in EU’s pharma industry.
A preliminary report by the European Commission has revealed that blocking and delaying tactics of generic products by global drug companies have cost EU citizens about 3 billion euros every year. The Commission had launched a sector inquiry earlier this year, in the light of indication that there was a noticeable decline in the number of novel medicines reaching the market. From a study conducted across 17 EU states, the average of 40 per year (in the years 1995-1999), the […]
Prelim report points to anti-competitive practices in EU’s pharma industry. Read More »

